Presents Three Abstracts for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO NANTES, France - ...

The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...

For decades, people in this area have been dealing with unusually high rates of serious health problems, such as multiple sclerosis, ulcerative colitis, Crohn’s disease, and various ...

Piper Sandler analyst maintains an Overweight rating on Teva, citing positive feedback on duvakitug's potential in treating ...

The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...

Reports Q4 revenue $4.2B, consensus $4.12B. Richard Francis, Teva‘s (TEVA) President and CEO, said: “2024 marked a transformative year for ...

NET PROFIT FORECAST: Takeda is expected to post a 59% drop in net profit to 43.58 billion yen, equivalent to $280.2 million, for the three months ended Dec. 31, according to a poll of analysts by data ...

The FDA has accepted Alvotech (ALVO) and Teva's (TEVA) applications for AVT05, their proposed biosimilar to J&J's ...

Exposure to various air pollutants, such as PM2.5 and nitrogen oxides, increases the risk for several autoimmune diseases, including psoriasis, lupus and rheumatoid arthritis, according to data ...

2025 Q3 Financial Results (as of September 30, 2025) ...

Galapagos (0JXZ – Research Report) received a Sell rating and a €22.00 price target from Barclays analyst Emily Field today. The company’s ...

Shares of Teva Pharmaceutical Industries ( TEVA -13.03%) were slipping Wednesday. The company's stock lost 13.5% as of 1:15 p ...